Inhaled nicotine replacement therapy

Asian Journal of Pharmaceutical Sciences

Volumn 10, Issue 6, 2015, Pages 472-480

  Cipolla, David ^a   Gonda, Igor ^a  

^a ARADIGM CORPORATION   (United States)

Author keywords

AERx system; Inhalation delivery; Nicotine; Smoking cessation; Staccato; Voke inhaler

Indexed keywords

NICOTINE; NICOTINE PATCH;

DRUG EFFICACY; ELECTRONIC CIGARETTE; METERED DOSE INHALER; NICOTINE REPLACEMENT THERAPY; NONHUMAN; REVIEW; SMOKING CESSATION; TOBACCO DEPENDENCE; WITHDRAWAL SYNDROME;

EID: 84959506173     PISSN: 18180876     EISSN: 2221285X     Source Type: Journal    
DOI: 10.1016/j.ajps.2015.07.004     Document Type: Review

References (40)

1. Center for Disease Control and Prevention Smoking and tobacco use accessed 01.07.15. http://www.cdc.gov/tobacco/data_statistics/fact_sheets/fast_facts/index.htm.
2. American Lung Association Information page on Tobacco accessed 01.07.15. http://www.lung.org/associations/states/colorado/tobacco/.
3. World Health Organization Tobacco in China accessed 01.07.15. http://www.wpro.who.int/china/mediacentre/factsheets/tobacco/en/.
4. World Health Organization http://www.who.int/mediacentre/factsheets/fs339/en/.
5. US Department of Health and Human Services 2014 Surgeon General's Report: the health consequences of smoking: fifty years of progress accessed 01.07.15. http://www.cdc.gov/tobacco/data_statistics/sgr/50th-anniversary/index.htm.
6. US Department of Health and Human Services 2004 Surgeon General's Report: the health consequences of smoking: a report of the surgeon general accessed 01.07.15. http://www.cdc.gov/tobacco/data_statistics/sgr/2004/index.htm.
7. US Department of Health and Human Services 2010 Surgeon General's Report: how tobacco smoke causes disease: the biology and behavioral basis for smoking-attributable disease accessed 01.07.15. http://www.cdc.gov/tobacco/data_statistics/sgr/2010/index.htm.
8. Alpert H., Connolly G., Biener L. Prospective cohort study challenging the effectiveness of population-based medical intervention for smoking cessation. Tob Control 2012, 22:32-37.
9. Caldwell B., Summer W., Crane J. A systematic review of nicotine by inhalation: is there a role for the inhaled route?. Nicotine Tob Res 2012, 14:1127-1139.
10. Cipolla D., Bruinenberg P., Eliahu P., et al. Development of an inhaled AERx Essence nicotine product for smoking cessation. Respiratory drug delivery 2008 2008, 365-369. Davis Healthcare Int'l Publishing LLC, River Grove. R.N. Dalby, P.R. Byron, J. Peart (Eds.).
11. Lunell E., Molander L., Ekberg K., et al. Site of nicotine absorption from a vapour inhaler - comparison with cigarette smoking. Eur J Clin Pharmacol 2000, 55:737-741.
12. Rigotti N.A. Treatment of tobacco use and dependence. N Engl J Med 2002, 346:506-512.
13. Moyses C., Hearn A., Redfern A. Evaluation of a novel nicotine inhaler device. Part 1: arterial and venous pharmacokinetics. Nicotine Tob Res 2015, 18-25.
14. Timmons R.D., Simis K.S., Lei M., et al. Feasibility study of nicotine aerosol generation using the staccato system. Respiratory drug delivery 2008 2008, 359-363. Davis Healthcare Int'l Publishing LLC, River Grove. R.N. Dalby, P.R. Byron, J. Peart (Eds.).
15. US Food and Drug Administration Regulation of e-cigarettes and other tobacco products April 25, accessed 01.07.15. http://www.fda.gov/NewsEvents/PublicHealthFocus/ucm252360.htm.
16. Benowitz N.L. The regulatory challenge of electronic cigarettes. JAMA 2013, 310:685-686.
17. Grana R., Benowitz N., Glantz S. E-cigarettes: a scientific review. Circulation 2014, 129:1972-1986.
18. Center for Disease Control and Prevention Morbidity and mortality weekly report April 4, accessed 01.07.15. http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6313a4.htm?s_cid=mm6313a4_w.
19. Grana R.A., Popova L., Ling P.M. A longitudinal analysis of electronic cigarette use and smoking cessation. JAMA Intern Med 2014, 174:812-813.
20. McRobbie H., Bullen C., Hartmann-Boyce J., et al. Electronic cigarettes for smoking cessation and reduction. Cochrane Database Syst Rev 2014, (12). CD010216.
21. Okona-Mensah K., Fayokun R. Environmental tobacco smoke and cancer. Encyclopedia of environmental health 2011, 528-541. Elsevier. J.O. Nriagu (Ed.).
22. Benowitz N.L. Clinical pharmacology of nicotine: implications for understanding and treating tobacco addiction. Clin Pharmacol Ther 2008, 83:531-541.
23. Cipolla D., Chan H.K., Schuster J., et al. Personalized medicine: development of inhalation systems tailored to the individual. Ther Deliv 2010, 1:667-682.
24. Gonda I., Bruinenberg P., Mudumba S., et al. Smoking cessation approach via deep lung delivery of 'clean' nicotine. RDD Europe 2009 2009, 57-61. Davis Healthcare Int'l Publications, River Grove. R.N. Dalby, P.R. Byron, J. Peart (Eds.).
25. Gonda I. Targeting by deposition. Pharmaceutical inhalation aerosol technology 1992, 61-82. Marcel Dekker, New York. A.J. Hickey (Ed.).
26. Cipolla D., Johansson E. AERx pulmonary drug delivery systems. Drugs and the pharmaceutical sciences. Modified release drug delivery technology 2008, 563-572. Informa Healthcare. 2nd ed. M.J. Rathbone, J. Hadgraft, M.S. Roberts (Eds.).
27. Vansickel A.R., Cobb C.O., Weaver M.F., et al. A clinical laboratory model for evaluating the acute effects of electronic "cigarettes": nicotine delivery profile and cardiovascular and subjective effects. Cancer Epidemiol Biomarkers Prev 2010, 19:1945-1953.
28. Caldwell B., Dickson S., Burgess C., et al. A pilot study of nicotine delivery to smokers from a metered dose inhaler. Nicotine Tob Res 2009, 11:342-347.
29. Armitage A.K., Dollery C.T., George C.F., et al. Absorption and metabolism of nicotine from cigarettes. Br Med J 1975, 4:313-316.
30. Farsalinos K.E., Spyrou A., Tsimopoulou K., et al. Nicotine absorption from electronic cigarette use: comparison between the first and new generation devices. Sci Rep 2014, 4:4133.
31. Cipolla D., Gonda I. Formulation technology to repurpose drugs for inhalation delivery. Drug Discov Today Ther Strateg 2011, 8:123-130.
32. Ong H.X., Traini D., Loo C.Y., et al. Is the cellular uptake of respiratory aerosols delivered from different devices equivalent?. Eur J Pharm Biopharm 2015, 10.1016/j.ejpb.2015.04.012.
33. Cipolla D., Bruinenberg P., Gonda I., et al. Deeper lung pulmonary delivery of treprostinil is associated with delayed systemic absorption. J Aer Med Pulm Drug Del 2011, 24(3):A16. Abstract O-047.
34. Silcock A., Gonzalez R., Gulta R., et al. A new nicotine inhaler device: delivered dose, composition and stability of formulation 2015, 21st Annual Meeting of the Society of Research on Nicotine and Tobacco, 23.
35. Silcock A., Gonzalez R., Gulta R., et al. A new nicotine inhaler device: triggering Range and Fine Particle Dose 2015, 21st Annual Meeting of the Society of Research on Nicotine and Tobacco, 22.
36. Moyses C., Hearn A., Redfern A. Evaluation of a novel nicotine inhaler device. Part 2: effect on craving and smoking urges. Nicotine Tob Res 2015, 26-33.
37. Noymer P., Biondi S., Myers D., et al. Pulmonary delivery of therapeutic compounds for treating CNS disorders. Ther Deliv 2011, 2:1125-1140.
38. Spyker D.A., Riesenberg R.A., Cassella J.V. Multiple dose pharmacokinetics of inhaled loxapine in subjects on chronic, stable antipsychotic regimens. J Clin Pharmacol 2015, 10.1002/jcph.502.
39. Kind Consumer Press Release dated September 12, accessed 01.07.15. http://www.kindconsumer.com/media/blog-and-news/first-regulatory-authorisation-voke%C2%AE-nicotine-inhaler.
40. Kind Consumer Press Release dated June 12, accessed 01.07.15. http://www.kindconsumer.com/media/blog-and-news/kind-consumer-limited-%E2%80%93-mhra-authorisation-determines-position-regulation.